Clinical trials: Advanced Hodgkin Lymphoma
Breast Cancer, Lymphoma
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Filgrastim and stem cell factor may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's…
- Trial name
- NCT00005993
- Testing
- aldesleukin, filgrastim, recombinant human stem cell factor
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hodgkin´s Lymphoma
HD12 for Advanced Stages
This study is designed to test (1) whether the BEACOPP dosage can be reduced to baseline in the last 4 cycles without loss of effectiveness, and (2) whether consolidating irradiation is necessary following effective chemotherapy.
- Trial name
- NCT00265031
- Testing
- Cyclophosphamide, Adriamycin, Etoposide
- Sponsor
- University of Cologne
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors.
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Malignant Mesothelioma, Advanced
- Trial name
- NCT03212404
- Testing
- CK-301 (cosibelimab)
- Where
- 48 sites in Australia, France and 7 more
- Volunteers
- 272 people
- Sponsor
- Checkpoint Therapeutics, Inc.
Advanced Solid Tumors, Cancer
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for…
- Conditions
- Advanced Solid Tumors, Cancer, Hematologic Malignancies
- Trial name
- NCT03082209
- Testing
- ABBV-621, Venetoclax, Bevacizumab
- Where
- 19 sites in United States, Japan and 2 more
- Volunteers
- 153 people
- Sponsor
- AbbVie
Solid Tumors, Multiple Myeloma
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
The purpose of this study is to assess the safety and tolerability of the investigational anticancer drug DCR-MYC. DCR-MYC is a novel synthetic double-stranded RNA in a stable lipid particle suspension that targets the oncogene…
- Conditions
- Solid Tumors, Multiple Myeloma, Non-Hodgkins Lymphoma, Pancreatic Neuroendocrine Tumors
- Trial name
- NCT02110563
- Testing
- DCR-MYC
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Diffuse Large B-cell Lymphoma
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
The purpose of this Phase I/II study is to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and to evaluate the safety, antitumor activity and pharmacokinetic (PK) profile of MAK683 in patients…
- Trial name
- NCT02900651
- Testing
- MAK683
- Where
- 16 sites in United States, Canada and 8 more
- Volunteers
- 139 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Studying TAK-243 in Patients With Advanced Cancer
This phase I trial studies the side effects and best dose of ubiquitin-activating enzyme (UAE) inhibitor TAK-243 (TAK-243) in treating patients with a solid tumor that may have spread from where it first started to nearby tissue…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Indolent Non-Hodgkin Lymphoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT06223542
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Non-small Cell Lung Cancer
A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.
This study was a randomized, single dose crossover comparison of the investigational product with a Reference Product (vinorelbine tartrate injection, NAVELBINE®).
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Non-Hodgkins Lymphoma
- Trial name
- NCT00432562
- Testing
- Vinorelbine Tartrate
- Where
- 5 sites in Argentina
- Volunteers
- 31 people
- Sponsor
- Mast Therapeutics, Inc.
Non-Hodgkin Lymphoma
Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma
The study evaluates the additional use of radioimmunotherapy with a 90-Yttrium labeled monoclonal antibody targeting lymphoma cells in two dose reduced conditioning regimens for allogeneic hematopoietic cell transplantation from…
- Trial name
- NCT00302757
- Testing
- Radioimmunotherapy, allogeneic hematopoietic cell transplantation
- Where
- 11 sites in Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital Tuebingen
Classical Hodgkin Lymphoma
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
This is a prospective single-arm, multi-center and phase II clinical trial to observe the efficacy and safety of Camrelizumab combined with AVD in the first-line treatment for patients with advanced classical Hodgkin's lymphoma.
- Trial name
- NCT04067037
- Testing
- Camrelizumab, Epirubicin, Vincristine
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Advanced Cancer
Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas
The study of Dariniparsin (ZIO-101-C) in Advanced Solid Tumors and Non-Hodgkin's Lymphomas
- Trial name
- NCT00591422
- Testing
- ZIO-101-C (Darinaparsin)
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Alaunos Therapeutics
Chondrosarcoma, Chondrosarcoma, Grade 2
AG-120 in People With IDH1 Mutant Chondrosarcoma
This study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.
- Conditions
- Chondrosarcoma, Chondrosarcoma, Grade 2, Chondrosarcoma, Grade 3, IDH1 Gene Mutation
- Trial name
- NCT04278781
- Testing
- AG-120
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer, Breast Cancer
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
This is a Phase 1, first-in-human, dose escalation study in participants with advanced solid tumors to determine the pharmacokinetics, maximum tolerated dose and the recommended Phase 2 dose of ABBV-075 at different monotherapy…
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Acute Myeloid Leukemia (AML)
- Trial name
- NCT02391480
- Testing
- ABBV-075, Venetoclax
- Where
- 10 sites in United States
- Volunteers
- 128 people
- Sponsor
- AbbVie
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies
This study is to evaluate the highest tolerated dose, safety and activity of HCD122 in adults with non-Hodgkin's or Hodgkin's lymphoma who have received at least two prior therapies.
- Trial name
- NCT00670592
- Testing
- HCD122
- Where
- 28 sites in United States, Australia and 9 more
- Volunteers
- 111 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
This phase I trial studies the side effects and best dose of GSK525762C (molibresib besylate) and entinostat in treating patients with solid tumors or lymphomas that have spread to other parts of the body (advanced) or are not…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III T-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT03925428
- Testing
- Entinostat, Molibresib
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can find cancer cells and carry cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00107380
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 78 sites in United States
- Volunteers
- 86 people
- Sponsor
- SWOG Cancer Research Network
Lymphoma
Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, and prednisone, work in different ways to stop…
- Trial name
- NCT00428142
- Testing
- rituximab, bortezomib, cyclophosphamide
- Where
- 19 sites in Canada
- Volunteers
- 95 people
- Sponsor
- NCIC Clinical Trials Group
B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
This is an open-label Phase 1 study to determine the feasibility, safety, and the recommended maximum tolerated Dose (MTD) of a single infusion of RPM CD19 mbIL15 CAR-T cells for adult patients.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Primary Mediastinal Large B Cell Lymphoma
- Trial name
- NCT04844086
- Testing
- RPM CD19-mbIL15-CAR-T cells
- Where
- Taiwan
- Volunteers
- 2 people
- Sponsor
- Eden BioCell Ltd.
Cutaneous T-cell Lymphoma (CTCL)
A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma
This is an open label, randomized phase II study designed to evaluate the tolerability and response rate of high-dose and low-dose regimens in patients with advanced cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT00476554
- Testing
- Sapacitabine
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Hodgkin's Disease
Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma
The objectives of this study are to assess the feasibility and efficacy of a combination chemotherapy (PVAG) in elderly patients with advanced stages Hodgkin's lymphoma.
- Trial name
- NCT00147875
- Testing
- Prednisone, Vinblastine, Doxorubicin (Adriamycin)
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University of Cologne